OxTalks will soon be transitioning to Oxford Events (full details are available on the Staff Gateway). A two-week publishing freeze is expected in early Hilary to allow all events to be migrated to the new platform. During this period, you will not be able to submit or edit events on OxTalks. The exact freeze dates will be confirmed as soon as possible.
If you have any questions, please contact halo@digital.ox.ac.uk
Recently the University of Oxford signed a partnership with Apollo Therapeutics.
Apollo Therapeutics – a biopharmaceutical portfolio company – will work closely with the University of Oxford to help its academics translate their research into novel, first-in-class therapeutics for patients. The collaboration aims to de-risk and accelerate the development of academic research ideas along the translation pathway. The range of therapeutics Apollo are interested in is fairly broad, spanning small molecules, biologics and vaccines. Additionally, the stage at which Apollo seek to engage with research is similarly broad, and encompasses early target discovery and validation through to clinical trials. The company are disease agnostic.
Come along if you’re interested to learn more about Apollo Therapeutics or interested in collaborating with them.
